Form 4 for KURA Kura Oncology, Inc.
Accepted 2022-11-18 00:00:00 ET · period of report 2022-11-17 · accession 0001209191-22-057874 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-11-18 | 2022-11-17 | KURA | Bair Teresa Brophy | CLO | S - Sale | $15.22 | -2,100 | 0 | -100% | -$32.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | S | D | 2,100 | $15.22 | 0 | D | — | — | (F2) 2,100 shares were acquired on November 17, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. (F3) This transaction was executed in multiple trades at prices ranging from $15.08 to $15.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |